SCHOFIELD, Wis., May 23, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced that Ludlow Research re-issued its research opinion on the company based on low market capitalization valuation.
- Non-Prescription, All Natural Product to Treat Migraine Headaches
- Clinical Trials Show the Product Outperforms #1 Prescription Competitor
- Currently Available Nationwide at Walgreen's and CVS/pharmacy stores
- Launching Marketing and Distribution Campaign
- Expanding Retail-Chain-Store Distribution
- Holds Patent on Product
- 38 Million Shares Outstanding
- Market Cap just under $1 Million
As of May 14, 2013, PuraMed BioScience had approximately 37.9 million common shares outstanding, thus giving the stock a market cap valuation of an estimated $721,756.
PuraMed BioScience currently has LipiGesic® M, an over-the-counter migraine pain reliever, distributed in Walgreens and CVS/pharmacy stores nationwide. The Company plans to expand that retail placement to an additional 21,000 targeted retail outlets, including mass merchandisers such as Wal-Mart and Target; food-store chains such as SuperValu, Kroger, and Safeway; as well as selected regional drugstore chains.
With an estimated 39 million Americans suffering from migraine headaches, the revenue prospects for PuraMed BioScience could be explosive.
"The first thing to consider is that people who suffer the excruciating pain of migraine are actively looking for a product that will relieve their migraine pain and associated symptoms," said Russ Mitchell , CEO of PuraMed BioScience. "The second point to consider is
Page: 1 2 3 Related biology technology :1
|SOURCE PuraMed BioScience, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO2
. Fitzsimons Redevelopment Authority Rolls Out First Phase of Strategic Refocus With Appointment of Four Key Leaders in The Bioscience Industry to Its Board of Directors3
. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer4
. Kansas Bioscience Authority Announces FY11 Outcomes of $207 Million5
. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.6
. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference7
. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology8
. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting9
. Ohios Bioscience Industry Effort Paying Off With Increase in Graduates and Accolades for the State10
. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference11
. Roka Bioscience Secures $47.5 Million in Series D Financing